(Q31942452)

5 July 2017

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia (English)

1 reference

5 July 2017

1 reference

Wolfe ML

1

1 reference

5 July 2017

Vartanian SF

2

1 reference

5 July 2017

Ross JL

3

1 reference

5 July 2017

Bansavich LL

4

1 reference

5 July 2017

Mohler ER 3rd

5

1 reference

5 July 2017

Meagher E

6

1 reference

5 July 2017

Friedrich CA

7

1 reference

5 July 2017

Rader DJ

8

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

American Journal of Cardiology

5 July 2017

1 reference

5 July 2017

87

1 reference

5 July 2017

476-9, A7

1 reference

5 July 2017

4

1 reference

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

5 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Epidemiology of triglycerides: a view from Framingham

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Pathophysiology and management of low high-density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Transient focal hepatic defects related to sustained-release niacin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Niacin-induced hepatotoxicity: unusual presentations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Hepatotoxicity associated with sustained-release niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Treatment of hyperlipidemia with combined niacin-statin regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Lovastatin, nicotinic acid, and rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Efficacy and safety of an extended-release niacin (Niaspan): a long-term study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

Plasma triglyceride and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901410-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(00)01410-7

1 reference

5 July 2017

1 reference